Skip to content

Lactated Ringer's Solution in Neonates With Feeding Intolerance

Enteral Administration of Lactated Ringer's Solution in Neonates With Feeding Intolerance, a Randomized Controlled Trial

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01236833
Acronym
LR
Enrollment
60
Registered
2010-11-09
Start date
2010-11-30
Completion date
2012-09-30
Last updated
2011-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intestinal Disease, Feeding Disorder Neonatal

Keywords

Lactated Ringer's Solution, Isotonic Solution, Intestinal Disease, Feeding Intolerance, Necrotizing Enterocolitis, Newborn, Premature Infant

Brief summary

The objective of this study is determining if enteral administration of Lactated Ringer's solution (LR) in preterm infants with feeding intolerance enables for faster advancement of milk feeding than fasting.

Detailed description

Feeding intolerance is a common problem in premature infants in the Neonatal Intensive Care Unit. Definition is clinical and based on abdominal distension, abdominal tenderness, emesis, change in gastric residuals, presence of blood in stool, and apnea with bradycardia. Feeding intolerance is associated with serious complications: necrotizing enterocolitis, longer hospitalization and prolonged intravenous nutrition complications (e.g. sepsis, liver damage). Therefore, the investigators aim to achieve adequate enteral nutrition as soon as possible. Because LR is a an amniotic fluid-like solution, it may improve gastro-intestinal function and avoid fasting, as well as its multiple problems (e.g. intestinal atrophy and decreased intestinal motility). LR was chosen as the test solution because of experience documenting its safe use in comparable groups: in newborn resuscitation parenterally, in amnioinfusion, and in bowel irrigation. Moreover, LR is similar in electrolytes composition to the experimental solution used in previous studies by Barney et al in neonates.

Interventions

2.5 ml per kg every 3 hours, via nasogastric tube, orogastric tube or orally, until the infant reaches 80 ml/kg/day of milk feeding or for a maximum of 14 days

Sponsors

McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
2 Days to No maximum
Healthy volunteers
No

Inclusion criteria

* Birth gestational age (GA) between 25 and 32 weeks * Corrected gestational age less than 34 weeks * Enteral feeding tolerated at a minimum of 10 ml/kg/day for a minimum of 48 hours * Severe feeding intolerance, defined as a minimum of one or more of the following signs leading to withholding of milk feedings on two evaluations over 12 to 24 hours: 1. Significant increased abdominal girth, as evaluated by the treatment team, with abdominal tenderness 2. Visible enlarged bowel loops with abdominal tenderness 3. Recurrent emesis leading to withhold feeds 4. Gastric residuals in excess of one feeding, recurrent or with growing abdominal girth 5. Visible blood in stools without anal etiology * Documented informed consent for participation in the study

Exclusion criteria

* Infants who already reached full enteral feeds for 72 hours, in fact a minimum of 130 ml/kg/day enteral feeds without parenteral supplementation. * Small for gestational age (SGA) (weight at or less than the 3rd percentile on the Fenton growth chart) * NEC (Bell's stage II or higher, radiologic evidence of NEC, pneumatosis intestinalis or free intraperitoneal air)or history of NEC * Gastric or intestinal occlusion (no transit, absent bowel sounds, incessant vomiting, bile stained vomiting or air fluid levels) * Major congenital malformation * Septic infants requiring therapeutic antibiotics or antimycotics (infants only on prophylactic antibiotics or antimycotics should not be excluded). * Patients judged as being too ill to enroll in this study, as defined by a requirement for mechanical ventilation with \>50% FIO2 * Patent Ductus Arteriosus requiring ibuprofen, indomethacin or ligature, until one week after the end of treatment * Intraventricular Haemorrhage grade 3 or 4 * Hypernatremia ≥ 150 mmol/L

Design outcomes

Primary

MeasureTime frameDescription
Average of the daily enteral caloric intake (in calories/kg/day) received over the 14 days after study entry14 daysTo measure enteral caloric intake, the volume of milk feeding, for each patient will be recorded daily and for 14 days. Unfortified milk and fortified milk are calculated as containing respectively 0.67 Cal/ml and 0.81 Cal/ml.

Secondary

MeasureTime frame
Number of days to discontinue IV accessvariable
Growth (weight, height, head circumference), increase % after 14 days and between study entry and discharge homevariable
Length of hospitalizationvariable
Number of days to reach 130 ml/kg milk feedingvariable
Electrolytes, bilirubin, serum urea nitrogen, creatinine and liver enzymes14 days
Infectionsuntil discharge
Necrotizing enterocolitisduring the 14 day-study period and hospitalization

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026